NCT00609739 · OUTCOME

Disease-free Survival

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participants
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

Number of patients who were free of disease and alive at 1 year.

Groups in this outcome

Cytarabine + Mitoxantrone

Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cytarabine + Mitoxantrone	1

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cytarabine + Mitoxantrone	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

anticipated Posting Date

2011-08

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
1
units
Participants

description

Number of patients who were free of disease and alive at 1 year.

groups

description
Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
id
OG000
title
Cytarabine + Mitoxantrone

param Type

NUMBER

reporting Status

POSTED

time Frame

1 year

title

Disease-free Survival

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice